PaySpan appoints Rex Adams as incoming CEO

– USA, GA – PaySpan®, Inc., the leading provider of health care reimbursement and payment automation, today announced the appointment of Rex Adams as Chief Executive Officer, replacing Kevin Arner.

Mr. Adams’ extensive operational experience and senior leadership roles in organizations including Children’s Healthcare of Atlanta, CareCentrix, WellCare Health Plans, AT&T and BellSouth are well suited to continue PaySpan’s rapid growth and expansion. Mr. Adams’ breadth of experience crosses operations, information technology, product development and management, and strategy and corporate planning. Mr. Adams is a graduate of the United States Military Academy at West Point and Harvard Business School.

PaySpan’s leading health care payment and financial services solutions are utilized by over 950 health plans and over 700,000 health care provider payees, representing the largest health care payment connectivity network in the nation.

ABS Capital Partners, a leading growth equity firm, is PaySpan’s majority owner and continues to support the Company’s rapid growth and leadership position.

About PaySpan

With more than 25 years of payments expertise, PaySpan® is a trusted source of innovative health care reimbursement solutions that Empower the Healthcare Economy® for health plans, providers, members and banks. PaySpan’s solutions enable stakeholders to interact across communities, conduct commerce, capture value, instill trust and strategically use reimbursement currency strategically. PaySpan’s customers comprise an elite array of industry leaders, representing all benefit types, spanning both commercial and government sectors.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>